"It is likely that CMS will continue to develop initiatives that include pricing transparency through alternative payment models like bundled payments and/or stand-alone initiatives like the physician and hospital data releases. Stakeholders, especially those in the medical technology and biopharmaceutical spaces from laboratories to drug manufacturers, have also been the subject of recent scrutiny. This indicates that future CMS efforts could further apply transparency initiatives as policymakers and commercial payers alike focus on innovative but very expensive therapies, devices, and diagnostics."  MORE >>